Study of Crizotinib for ROS1 and MET Activated Lung Cancer

To join this study, you would need to be an adult, aged 18 or older, and have advanced non-small cell lung cancer that has spread and cannot be cured with surgery. Importantly, your cancer must have specific gene changes in either ROS1 or MET, which would be identified through tests. You should generally be in good health otherwise, able to manage daily activities, and have important organs like your heart and blood working well.

There are also some reasons why you might not be able to join. For example, if you have untreated cancer that has spread to your brain causing symptoms, or if you've recently had other cancer treatments like chemotherapy or radiotherapy, you might not be eligible. We would also need to check if you have any conditions or are taking any medicines that might interfere with crizotinib.

If you decide to join this study, it would begin with a 'screening period'. During this time, you'll have various tests and check-ups to make sure the study drug is right for you. This might involve several visits. If you are suitable, you’d then move into the 'study drug period', where you'll take crizotinib as prescribed. During this time, you would have regular appointments, likely about once a week at first, for further tests to monitor your health and see how the drug is working.

If you need to stop taking the study drug early for any reason, you'll have a final visit about a month later for safety check-ups. After stopping the drug, we would continue to monitor your cancer with scans every 8 weeks if your cancer hasn't progressed. Following all treatments and close monitoring, the study team will then call you approximately every three months to check on your general health. The total duration of your participation would depend on how your treatment progresses.